Payden & Rygel’s PDL BioPharma, Inc. PDLI Stock Holding History

Payden & Rygel’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-650	Closed	-$4K	–	203
2015 Q2	$4K	Hold	650	–	–	﹤0.01%	196
2015 Q1	$5K	Hold	650	–	–	﹤0.01%	204
2014 Q4	$5K	Hold	650	–	–	﹤0.01%	202
2014 Q3	$5K	Hold	650	–	–	﹤0.01%	205
2014 Q2	$6K	Hold	650	–	–	﹤0.01%	216
2014 Q1	$5K	Buy	+650	New	+$5.57K	﹤0.01%	213

Other funds holding PDLI

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Payden & Rygel's PDLI Position: Q3 2015 in Review

Payden & Rygel sold out of PDL BioPharma, Inc. (PDLI) in Q3 2015, closing a stake of 650 shares — an estimated $4K sold.

Payden & Rygel first reported a position in PDLI in Q1 2014 and held it in 6 quarters. The position peaked at $6K in Q2 2014. 213 funds tracked by Wall St. Rank hold PDLI as of Q3 2015.

Payden & Rygel reported no remaining PDL BioPharma, Inc. position as of Q3 2015 after selling out during the quarter.
Payden & Rygel sold 650 PDL BioPharma, Inc. shares in Q3 2015, an estimated $4K.
Payden & Rygel first reported a position in PDL BioPharma, Inc. in Q1 2014 and held it in 6 quarters.
Payden & Rygel's PDL BioPharma, Inc. position peaked at $6K in Q2 2014.
213 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2015.

Based on Payden & Rygel's 13F filing for Q3 2015, filed 2 Nov 2015.